← All patient Q&A hubs

Top 10 Tirzepatide Questions from Reddit, Answered with Trial Data

Last verified 2026-05-27 · 10 questions · 11 PubMed citations

This page pulls high-upvote patient questions from r/tirzepatidecompound, r/Zepbound, r/Mounjaro about tirzepatide and answers each with peer-reviewed trial data, FDA-label evidence, and current editorial analysis. Every answer cites at least one PubMed ID and links to the original Reddit source thread.

Question sources: r/tirzepatidecompound, r/Zepbound, r/Mounjaro

Questions and answers

If I stop tirzepatide, will the weight come back?

Most patients regain a meaningful portion of the lost weight after stopping. In SURMOUNT-4, a randomized withdrawal trial, adults who had already lost about 20.9% of their starting weight on tirzepatide during a 36-week lead-in were then randomized either to continue the drug or switch to placebo for another year. Patients who continued tirzepatide lost another 5.5% on top, for total weight loss around 25%. Patients switched to placebo regained roughly 14% of their body weight, ending with net loss closer to 9.9% (SURMOUNT-4, Aronne 2024, PMID 38078870). The pattern matches what is seen across the GLP-1 class: tirzepatide treats obesity the way blood-pressure medication treats hypertension, not the way an antibiotic treats an infection. Some weight regain is expected unless food intake, activity, and sleep changes are maintained. Trials show that staying on a maintenance dose, even a lower one, blunts regain compared with stopping cold. Plan for a long taper conversation with your prescriber rather than an abrupt stop. None of this is medical advice; it summarizes what the withdrawal trial measured.

Source thread ↗3 upvotes on RedditCites: PMID 38078870

Does tirzepatide keep working long-term or does my body adapt?

Trial data through 72 weeks suggest tirzepatide keeps working as long as you stay on it; the visible plateau later in treatment is not the drug losing potency. In SURMOUNT-1, average weight loss at 15 mg was about 20.9% at 72 weeks, with the steepest drop in the first 6-9 months and a slower decline after that (SURMOUNT-1, Jastreboff 2022, PMID 35658024). Patients who continued tirzepatide in SURMOUNT-4 kept losing another 5.5% during a second year on drug, showing the effect does not simply stop at one year (Aronne 2024, PMID 38078870). What changes is the math: as you lose weight, daily calorie needs drop, so the same calorie deficit produces smaller weekly losses. A flat scale at month 14 usually reflects a smaller body and a smaller energy gap, not tachyphylaxis. If weight has been stable for 8-12 weeks at the maximum tolerated dose, that often is the new set point at this dose. Discuss whether a higher dose, longer duration, or other levers like resistance training make sense for you.

Source thread ↗4 upvotes on RedditCites: PMID 35658024, PMID 38078870

How do I know if my appetite suppression stopped, or if my body is fighting back?

Both can be true at the same time, and the trials suggest the second is usually the bigger driver. Tirzepatide reaches steady state after about 4 weeks at a given dose and produces consistent appetite reduction at that level (Phase 1 pharmacokinetic data, Feng 2023, PMID 37285081). Trials do not show tirzepatide losing its effect on hunger over time at a stable dose. What does happen is metabolic adaptation: as body weight falls, resting metabolic rate falls, hormones like ghrelin can rise, and the same dose is now treating a smaller body. SURMOUNT-1 showed the curve flatten after roughly 60 weeks even though patients stayed on full dose, consistent with adaptation rather than the drug wearing off (Jastreboff 2022, PMID 35658024). Practical check: if hunger has clearly increased in the last 4-8 weeks at a stable dose, talk with your prescriber about whether a dose increase, a structured higher-protein intake, or resistance training would help. If hunger is unchanged but the scale is just slower, that is consistent with a smaller body needing fewer calories.

Source thread ↗1 upvotes on RedditCites: PMID 35658024, PMID 37285081

Do nausea and other side effects get better, or should I stop?

For most patients in the trials, side effects peak during dose increases and ease over the following weeks. A pooled SURMOUNT-1/2 tolerability analysis found that nausea, diarrhea, and constipation were typically mild to moderate, occurred most often during dose escalation, and decreased over time as patients stayed at a given dose. Roughly 4-7% of patients on tirzepatide discontinued for adverse events in the main trials versus 2-3% on placebo, meaning the large majority finished the study (Rubino 2025 GI tolerability, PMID 39789843; SURMOUNT-1, Jastreboff 2022, PMID 35658024). The standard label titration of 4 weeks per dose was designed specifically to limit nausea. Patients who struggle at a given step often do better if their prescriber holds that dose an extra 4 weeks rather than escalating on schedule. Warning signs that warrant a prompt clinician call rather than waiting it out include severe persistent abdominal pain (possible pancreatitis), repeated vomiting with dehydration, signs of gallbladder disease, or symptoms of low blood sugar if you are on insulin or a sulfonylurea. Mild nausea fading week by week is the expected pattern.

Source thread ↗4 upvotes on RedditCites: PMID 39789843, PMID 35658024

Should I move up to the next dose or stay where I am?

Trial data support both staying and escalating, depending on the goal. SURMOUNT-1 showed dose-response: average weight loss at 72 weeks was about 15.0% at 5 mg, 19.5% at 10 mg, and 20.9% at 15 mg (Jastreboff 2022, PMID 35658024). Bigger doses produced more weight loss on average but also more gastrointestinal side effects, which is why the label titrates by 2.5 mg every 4 weeks. If you are still losing weight at a meaningful pace and tolerating the current dose, many clinicians will hold rather than push. If weight has been flat for 8-12 weeks at maximum tolerated dose and you still have weight to lose, that is the typical signal to discuss escalation. Side effects from a step-up usually peak in the first 1-2 weeks and ease over the following month. The trials did not test indefinite dose-holding versus stepping up, so the choice is individualized. A reasonable framing for a prescriber visit is: am I at goal, is the scale moving, and how tolerable is the current dose this week? None of this is medical advice.

Source thread ↗1 upvotes on RedditCites: PMID 35658024

Does tirzepatide help with anything besides weight loss?

Yes. Beyond weight loss, randomized trials have shown tirzepatide improves multiple obesity-related conditions. SURMOUNT-OSA found tirzepatide cut apnea-hypopnea index by about 25-29 events per hour in adults with moderate-to-severe obstructive sleep apnea and obesity, roughly half the baseline rate (Malhotra 2024, PMID 38912654). SYNERGY-NASH showed resolution of MASH (formerly NASH) without worsening fibrosis in 44-62% of tirzepatide patients versus 10% on placebo at 52 weeks (Loomba 2024, PMID 38856224). SUMMIT, in adults with heart failure with preserved ejection fraction and obesity, reduced cardiovascular death or worsening heart failure events compared with placebo (Packer 2025, PMID 39555826). SURPASS-2 in type 2 diabetes showed HbA1c reductions of 2.0-2.3 percentage points at higher doses (Frias 2021, PMID 34170647). A long-term SURMOUNT analysis also found that tirzepatide reduced progression to type 2 diabetes in adults with prediabetes and obesity (Jastreboff 2025, PMID 39536238). Many patients also report better blood pressure, lipids, and reflux, consistent with the cardiometabolic benefits seen in trials.

Source thread ↗51 upvotes on RedditCites: PMID 38912654, PMID 38856224, PMID 39555826, PMID 34170647, PMID 39536238

How does tirzepatide compare to semaglutide for weight loss?

Head-to-head data now exist. SURMOUNT-5 was a 72-week randomized trial of tirzepatide versus semaglutide at their maximum tolerated doses in adults with obesity but without type 2 diabetes. Mean weight loss was about 20.2% on tirzepatide versus 13.7% on semaglutide, a difference of about 6.5 percentage points favoring tirzepatide (Aronne 2025, PMID 40353578). For glucose control, SURPASS-2 compared tirzepatide to semaglutide 1 mg in type 2 diabetes and found tirzepatide reduced HbA1c more (about 2.0-2.3 vs 1.86 percentage points) and produced more weight loss (Frias 2021, PMID 34170647). Both drugs share the GLP-1 mechanism. Tirzepatide adds a second receptor (GIP), and several lines of evidence suggest the dual mechanism is part of why it produces larger average weight loss. That said, individual response varies. Gastrointestinal side effects, cost, and insurance coverage often determine which drug a patient actually stays on. Switching directions between the two is possible and is done in real-world practice, though it is not formally studied in randomized trials.

Source thread ↗3 upvotes on RedditCites: PMID 40353578, PMID 34170647

Can tirzepatide work during perimenopause or alongside HRT?

Tirzepatide was not specifically designed for menopause, but the SURMOUNT trials included large numbers of postmenopausal women and showed similar weight loss to other adults. In SURMOUNT-1, women made up about 67% of enrollees, and subgroup analyses did not show menopausal status meaningfully reducing efficacy (Jastreboff 2022, PMID 35658024). Hormone replacement therapy was not an exclusion criterion in SURMOUNT-1, and patients on stable HRT participated. There is no published evidence that HRT blocks tirzepatide or that tirzepatide blocks HRT. One known interaction is with oral contraceptives: tirzepatide slows gastric emptying, which can reduce absorption of orally dosed estrogen-containing pills. The FDA label specifically warns about reduced efficacy of oral contraceptives for 4 weeks after starting tirzepatide and after each dose increase, and recommends a barrier method or a non-oral contraceptive. This caution is for contraceptive pills specifically. For systemic HRT, transdermal patches and gels bypass the gut and are not expected to be affected. Discuss specifics with your prescriber.

Source thread ↗7 upvotes on RedditCites: PMID 35658024

Why am I more hungry on days 5, 6, and 7 after my shot?

Tirzepatide is a once-weekly injection with a half-life of about 5 days, so concentrations peak in the first 24-72 hours and then taper down toward the end of the week. In a phase 1 multiple-dose study, plasma concentrations declined steadily after each dose, with a noticeable drop in the back half of the dosing interval before the next injection restored levels (Feng 2023, PMID 37285081). Reduced appetite tracks roughly with drug exposure, so it is common and expected for patients to feel hungrier on days 5-7 than on days 1-3. After 4 weeks at a stable dose, you reach steady state and the swings get smaller, but a mild end-of-week rise in appetite is normal and is not a sign the drug has stopped working. Practical patterns patients report: pick a fixed weekly injection day, keep higher-protein and higher-fiber meals available for days 5-7, and avoid relying on willpower alone late in the week. If hunger surges feel severe enough to drive weight regain, talk to your prescriber about whether a dose adjustment is warranted, rather than changing the injection interval on your own.

Source thread ↗4 upvotes on RedditCites: PMID 37285081

Will I lose muscle on tirzepatide, and how much?

Most weight lost on tirzepatide is fat, but some loss of lean mass is expected, as it is with any meaningful weight loss. A SURMOUNT-1 body-composition substudy used DXA scans and found that, in adults who lost about 24% of body weight on tirzepatide, roughly 75% of the loss was fat mass and about 25% was lean mass (Look 2025, PMID 39996356). That fat-to-lean ratio is broadly similar to what is seen with diet-only weight loss, and the overall ratio of fat to lean mass at the end of the study actually improved because so much fat was lost. That does not mean every patient sees the same ratio. People who eat low protein, do little resistance training, or lose weight very fast may lose a higher share of lean mass. The standard counter-measures are evidence-based and inexpensive: aim for protein intake around 1.2-1.6 grams per kilogram of body weight per day, lift weights 2-3 times per week, and avoid extended very-low-calorie days. None of this is medical advice; it summarizes the imaging substudy.

Source thread ↗4 upvotes on RedditCites: PMID 39996356

Cited sources

References

  1. 1.Jastreboff AM, Aronne LJ, Ahmad NN, et al Tirzepatide Once Weekly for the Treatment of Obesity N Engl J Med. 2022. PMID: 35658024.
  2. 2.Aronne LJ, Horn DB, le Roux CW, et al Tirzepatide as Compared with Semaglutide for the Treatment of Obesity N Engl J Med. 2025. PMID: 40353578.
  3. 3.Malhotra A, Grunstein RR, Fietze I, et al Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity N Engl J Med. 2024. PMID: 38912654.
  4. 4.Frias JP, Davies MJ, Rosenstock J, et al Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes N Engl J Med. 2021. PMID: 34170647.
  5. 5.Loomba R, Hartman ML, Lawitz EJ, et al Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis N Engl J Med. 2024. PMID: 38856224.
  6. 6.Aronne LJ, Sattar N, Horn DB, et al Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial JAMA. 2024. PMID: 38078870.
  7. 7.Jastreboff AM, le Roux CW, Stefanski A, et al Tirzepatide for Obesity Treatment and Diabetes Prevention N Engl J Med. 2025. PMID: 39536238.
  8. 8.Rubino DM, Pedersen SD, Connery L, et al Gastrointestinal tolerability and weight reduction associated with tirzepatide in adults with obesity or overweight with and without type 2 diabetes in the SURMOUNT trials Diabetes Obes Metab. 2025. PMID: 39789843.
  9. 9.Look M, Dunn JP, Kushner RF, et al Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight Diabetes Obes Metab. 2025. PMID: 39996356.
  10. 10.Packer M, Zile MR, Kramer CM, et al Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity N Engl J Med. 2025. PMID: 39555826.
  11. 11.Feng P, Sheng X, Ji Y, et al A Phase 1 Multiple Dose Study of Tirzepatide in Chinese Patients with Type 2 Diabetes Adv Ther. 2023. PMID: 37285081.

Questions on this page are paraphrased from real patient discussions on the listed subreddits. Answers are editorial synthesis of peer-reviewed trial data, FDA labels, and our research desk’s analysis — not medical advice. Speak with your prescriber before changing any dose or regimen.

Browse all patient Q&A hubs, our Top-N PubMed lists, or our dose-ladder cheat sheets.